Hormone-related factors and breast cancer : studies of risk and prognosis
Author: Rosenberg, Lena
Date: 2006-09-08
Location: Samuelssonsalen, Tomtebodavägen 6, Karolinska Institutet, Solna
Time: 09.15
Department: Institutionen för medicinsk epidemiologi och biostatistik / Department of Medical Epidemiology and Biostatistics
View/ Open:
Thesis (605.6Kb)
Abstract
The main purpose of this thesis was to explore the influences of risk factors for breast cancer on breast cancer characteristics and survival.
We evaluated the associations between number and timing of births and breast cancer-specific survival using data from the Swedish Cancer Register, the Swedish Cause of Death Register, and the Multi-Generation Register. We identified more than 27,000 women born in Sweden and diagnosed with breast cancer in 1958-1997. We found a successively worse prognosis for women with a shorter delay between last birth and breast cancer diagnosis. Compared to women with their last birth more than 10 years before diagnosis, the risk of breast cancer death was increased by 72% for those with breast cancer diagnosis in the first year after last birth, and 39% for those diagnosed in the 3rd year after last birth.
Women with a first birth before 20 years had a slightly worse prognosis than parous women with their first birth between 20-24 years. These findings suggest that a recent birth and possibly an early first birth influence tumor biology.
For the three following studies we used a Swedish population-based case-control study including more than 3,000 women aged 50-74 diagnosed with breast cancer in 1993-1995, and more than 3,000 age-frequency matched controls. The study holds information from questionnaires, patient records, and the Swedish Cause of Death Register.
We assessed the influence of menopausal hormone therapy, anthropometric factors, reproductive factors, recent smoking, recent alcohol intake, family history of breast cancer, and previous benign breast disease on the risk of ductal, lobular, or tubular breast cancer. Menopausal estrogen-progestin therapy was associated with increased risks for all subtypes, but the estimates for lobular and tubular cancer were stronger compared to ductal cancer. Menopausal estrogen alone therapy was similarly associated with ductal and lobular breast cancer. Recent alcohol intake was significantly associated with tubular cancer, and seemed non-significantly related to lobular but not ductal breast cancer.
Increasing age at first birth was borderline significantly more strongly related to lobular compared to ductal breast cancer. Other reproductive factors, anthropometric factors, and smoking seemed similarly related to ductal and lobular breast cancer.
The same risk factors were also evaluated by joint estrogen (ER) and progesterone receptor (PR) status of the tumors. We found menopausal estrogen-progestin therapy to increase the risk for all receptor groups except the ER-PR- group. The risks were borderline significantly stronger for ER+PR+ tumors compared to ER-PR- tumors. Menopausal estrogen alone therapy was similarly associated with all receptor-defined groups. A high age at first birth seemed to increase the risk only for the ER+ groups, and substantial adult weight gain was associated only with the PR+ tumor groups. Most other risk factors seemed similarly associated with all receptor-defined tumor groups.
Current, but not past, compared to never use of menopausal hormone therapy was associated with tumors of low grade, low S-phase fraction, and improved breast cancer specific survival. The associations were stronger with longer duration, and breast cancer survival seemed more favorable with estrogen-progestin than estrogen alone therapy. The improved survival among current users of menopausal hormone therapy was only partly explained by differences in available tumor characteristics and mammography surveillance.
We evaluated the associations between number and timing of births and breast cancer-specific survival using data from the Swedish Cancer Register, the Swedish Cause of Death Register, and the Multi-Generation Register. We identified more than 27,000 women born in Sweden and diagnosed with breast cancer in 1958-1997. We found a successively worse prognosis for women with a shorter delay between last birth and breast cancer diagnosis. Compared to women with their last birth more than 10 years before diagnosis, the risk of breast cancer death was increased by 72% for those with breast cancer diagnosis in the first year after last birth, and 39% for those diagnosed in the 3rd year after last birth.
Women with a first birth before 20 years had a slightly worse prognosis than parous women with their first birth between 20-24 years. These findings suggest that a recent birth and possibly an early first birth influence tumor biology.
For the three following studies we used a Swedish population-based case-control study including more than 3,000 women aged 50-74 diagnosed with breast cancer in 1993-1995, and more than 3,000 age-frequency matched controls. The study holds information from questionnaires, patient records, and the Swedish Cause of Death Register.
We assessed the influence of menopausal hormone therapy, anthropometric factors, reproductive factors, recent smoking, recent alcohol intake, family history of breast cancer, and previous benign breast disease on the risk of ductal, lobular, or tubular breast cancer. Menopausal estrogen-progestin therapy was associated with increased risks for all subtypes, but the estimates for lobular and tubular cancer were stronger compared to ductal cancer. Menopausal estrogen alone therapy was similarly associated with ductal and lobular breast cancer. Recent alcohol intake was significantly associated with tubular cancer, and seemed non-significantly related to lobular but not ductal breast cancer.
Increasing age at first birth was borderline significantly more strongly related to lobular compared to ductal breast cancer. Other reproductive factors, anthropometric factors, and smoking seemed similarly related to ductal and lobular breast cancer.
The same risk factors were also evaluated by joint estrogen (ER) and progesterone receptor (PR) status of the tumors. We found menopausal estrogen-progestin therapy to increase the risk for all receptor groups except the ER-PR- group. The risks were borderline significantly stronger for ER+PR+ tumors compared to ER-PR- tumors. Menopausal estrogen alone therapy was similarly associated with all receptor-defined groups. A high age at first birth seemed to increase the risk only for the ER+ groups, and substantial adult weight gain was associated only with the PR+ tumor groups. Most other risk factors seemed similarly associated with all receptor-defined tumor groups.
Current, but not past, compared to never use of menopausal hormone therapy was associated with tumors of low grade, low S-phase fraction, and improved breast cancer specific survival. The associations were stronger with longer duration, and breast cancer survival seemed more favorable with estrogen-progestin than estrogen alone therapy. The improved survival among current users of menopausal hormone therapy was only partly explained by differences in available tumor characteristics and mammography surveillance.
List of papers:
I. Rosenberg L, Thalib L, Adami HO, Hall P. (2004). Childbirth and breast cancer prognosis. Int J Cancer. 111(5): 772-6.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. (2006). Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res. 8(1): R11.
Fulltext (DOI)
Pubmed
Fulltext (DOI)
III. Rosenberg LU, Einarsdóttir K, Isaksson Friman E, Wedrén S, Dickman PW, Hall P, Magnusson C (2006). Risk factors for hormone-receptor defined breast cancer in postmenopausal women. [Submitted]
IV. Rosenberg LU, Dickman PW, Einarsdóttir K, Persson I, Wedrén S,Granath F, Hall P (2006). Menopausal hormone therapy in relation to breast cancer characteristics and prognosis. [Submitted]
I. Rosenberg L, Thalib L, Adami HO, Hall P. (2004). Childbirth and breast cancer prognosis. Int J Cancer. 111(5): 772-6.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. (2006). Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res. 8(1): R11.
Fulltext (DOI)
Pubmed
Fulltext (DOI)
III. Rosenberg LU, Einarsdóttir K, Isaksson Friman E, Wedrén S, Dickman PW, Hall P, Magnusson C (2006). Risk factors for hormone-receptor defined breast cancer in postmenopausal women. [Submitted]
IV. Rosenberg LU, Dickman PW, Einarsdóttir K, Persson I, Wedrén S,Granath F, Hall P (2006). Menopausal hormone therapy in relation to breast cancer characteristics and prognosis. [Submitted]
Issue date: 2006-08-18
Rights:
Publication year: 2006
ISBN: 91-7140-821-5
Statistics
Total Visits
Views | |
---|---|
Hormone-related ...(legacy) | 1044 |
Hormone-related ... | 450 |
Total Visits Per Month
October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
Hormone-related ... | 28 | 13 | 17 | 15 | 13 | 26 | 9 |
File Visits
Views | |
---|---|
thesis.pdf(legacy) | 1562 |
thesis.pdf | 346 |
thesis.pdf.txt(legacy) | 2 |
Top country views
Views | |
---|---|
United States | 441 |
Sweden | 141 |
China | 91 |
United Kingdom | 77 |
Ireland | 76 |
Germany | 61 |
South Korea | 31 |
Russia | 31 |
Ukraine | 28 |
Denmark | 17 |
Top cities views
Views | |
---|---|
Dublin | 76 |
Ashburn | 55 |
Beijing | 47 |
Sunnyvale | 45 |
Seoul | 28 |
Kiez | 22 |
Sevastopol | 21 |
Ballerup | 16 |
Stockholm | 16 |
Moscow | 13 |